Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
VAPOTHERM INC (VAPO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/17/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 08/08/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/23/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"PRE-FUNDED WARRANT TO PURCHASE STOCK Company: Vapotherm, Inc., a Delaware corporation Warrant No. 2023-1 Number of Shares: [●], subject to adjustment Type/Series of Stock: Common Stock, $0.001 par value per share Warrant Price : $[●] per Share, subject to adjustment. The aggregate exercise price of this Warrant of $[●] per Share, except for a nominal exercise price of $0.001 per Share, was paid to the Company on or prior to the date of issuance of this Warrant and, consequently, no additional consideration shall be required to be paid by the Holder to effect any exercise of this Warrant. The Holder shall not be entitled to a refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the eve...",
"WARRANT TO PURCHASE STOCK Company: Vapotherm, Inc., a Delaware corporation Warrant No. 2023-1 Number of Shares: [●], subject to adjustment Type/Series of Stock: Common Stock, $0.001 par value per share Warrant Price : $[●] per Share, subject to adjustment Issue Date: February [●], 2023 Expiration Date: February [●], 2028 See also Section 5.1. THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [●] or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase up to the above-stated number of fully paid and non-assessable shares of the above-stated Type/Series of Stock of the above-named company at the above-stated Exercise Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subj...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 7, 2023, among Vapotherm, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, the Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended . WHEREAS, each Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, the number of shares of common stock, par value $0.001 per share, of the Company set forth opposite such Purchaser’s name on hereto, which aggregate number of shares of Common Stock for all Purchasers together shall be 17,502,244 shares of Common Sto...",
"Vapotherm Announces $23 Million Private Placement EXETER, New Hampshire, February 8, 2023 / Business Wire / -- Vapotherm, Inc. , , a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it has entered into a securities purchase agreement with a select group of institutional and accredited investors through a private placement financing for gross proceeds of approximately $23.0 million, before deducting fees to the placement agent and other offering expenses. Pursuant to the Purchase Agreement, the Company agreed to issue 17,502,244 shares of its common stock and pre-funded warrants to purchase up t..." |
|
| 02/08/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Vapotherm Reports Preliminary Fourth Quarter and Full Year 2022 Results and Year-End Cash Balance EXETER, New Hampshire, February 8, 2023 / Business Wire / -- Vapotherm, Inc. , , a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced preliminary unaudited fourth quarter and full year 2022 net results. Preliminary Fourth Quarter and Full Year 2022 Financial Results For the fourth quarter of 2022, the Company expects net revenue to be in the range of $18.4 million to $18.7 million. For the fourth quarter of 2022, the Company expects gross margin to be in the range of 27% to 28%. For the fourth quarter of ..." |
|
| 12/06/2022 |
8-K
| Quarterly results |
| 11/22/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
8-K/A
| Cost Associated with Exit or Disposal Activities Interactive Data |
| 08/03/2022 |
8-K
| Quarterly results |
| 07/11/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Quarterly results |
| 04/12/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"[Remainder of page intentionally left blank; signature page follows] IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective Date. AGREED AND ACCEPTED VAPOTHERM, INC. EXECUTIVE By: /s/ John R. Landry Title: Sr VP & CFO /s/ Joseph Army Joseph Army GENERAL RELEASE [●] , on behalf of the Executive and the Executive’s heirs, executors, administrators, successors and assigns, whether named or referred to below or not, releases, acquits and forever discharges Vapotherm, Inc. , its parent, successors and assigns, their agents, servants, and employees, its subsidiaries, divisions, subdivisions, and affiliates , of and from any and all past, present, and future claims, counterclaims, demands, actions, causes of action, liabilities, damages, costs, loss of s...",
"[Remainder of page intentionally left blank; signature page follows] IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective Date. AGREED AND ACCEPTED VAPOTHERM, INC. EXECUTIVE By: /s/ Joe Army Title: CEO /s/ John R. Landry John Landry GENERAL RELEASE [●] , on behalf of the Executive and the Executive’s heirs, executors, administrators, successors and assigns, whether named or referred to below or not, releases, acquits and forever discharges Vapotherm, Inc. , its parent, successors and assigns, their agents, servants, and employees, its subsidiaries, divisions, subdivisions, and affiliates , of and from any and all past, present, and future claims, counterclaims, demands, actions, causes of action, liabilities, damages, costs, loss of services, ex...",
"[Remainder of page intentionally left blank; signature page follows] IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective Date. AGREED AND ACCEPTED VAPOTHERM, INC. EXECUTIVE By: /s/ Joe Army Title: CEO /s/ Greg Ramade Greg Ramade GENERAL RELEASE [●] , on behalf of the Executive and the Executive’s heirs, executors, administrators, successors and assigns, whether named or referred to below or not, releases, acquits and forever discharges Vapotherm, Inc. , its parent, successors and assigns, their agents, servants, and employees, its subsidiaries, divisions, subdivisions, and affiliates , of and from any and all past, present, and future claims, counterclaims, demands, actions, causes of action, liabilities, damages, costs, loss of services, expen..." |
|
| 04/06/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/24/2022 |
8-K
| Quarterly results |
| 01/12/2022 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 01/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/06/2021 |
8-K
| Quarterly results |
| 11/03/2021 |
8-K
| Quarterly results |
| 09/27/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/09/2021 |
8-K
| Quarterly results |
| 06/24/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 02/24/2021 |
8-K
| Quarterly results |
| 01/13/2021 |
8-K
| Quarterly results |
| 12/01/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/04/2020 |
8-K
| Quarterly results |
| 10/23/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|